Magdalena JastrzÄbska-WiÄsek

List of Publications by Year
in descending order

61 papers	1,168 citations	393982 19 h-index	454577 30 g-index
63 all docs	63 docs citations	63 times ranked	1212 citing authors

#	Article	IF	Citations
1	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. European Journal of Medicinal Chemistry, 2013, 60, 42-50.	2.6	81
2	Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptorâ€"5-HT1A/5-HT2A/5-HT7 and D2/D3/D4â€"agents: The synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2012, 20, 1545-1556.	1.4	59
3	Activity of Serotonin 5-HT1A Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties. ACS Chemical Neuroscience, 2018, 9, 1040-1050.	1.7	47
4	The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment. International Journal of Molecular Sciences, 2019, 20, 3420.	1.8	43
5	N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. ACS Medicinal Chemistry Letters, 2016, 7, 618-622.	1.3	42
6	In the search for a lead structure among series of potent and selective hydantoin 5â€<scp>HT</scp>₇R agents: The drugâ€likeness in vitro study. Chemical Biology and Drug Design, 2017, 90, 1295-1306.	1.5	41
7	Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT1A and 5-HT7 Antagonists in Animal Models. PLoS ONE, 2015, 10, e0142499.	1.1	39
8	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT 7 receptor antagonist: In vitro drug-likeness studies and in vivo pharmacological evaluation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 878-883.	1.0	36
9	Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands. Bioorganic and Medicinal Chemistry, 2011, 19, 6750-6759.	1.4	33
10	The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine. European Journal of Medicinal Chemistry, 2017, 135, 117-124.	2.6	33
11	Anxiolytic-like activity of zinc in rodent tests. Pharmacological Reports, 2011, 63, 1050-1055.	1.5	32
12	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. Bioorganic and Medicinal Chemistry, 2015, 23, 212-221.	1.4	31
13	Derivatives of pyrrolo[3,4-d]pyridazinone, a new class of analgesic agents. European Journal of Medicinal Chemistry, 2011, 46, 4992-4999.	2.6	30
14	Towards new 5-HT 7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties. European Journal of Medicinal Chemistry, 2016, 108, 334-346.	2.6	28
15	5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801. Brain Research, 2019, 1722, 146375.	1.1	27
16	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. European Journal of Medicinal Chemistry, 2015, 92, 221-235.	2.6	26
17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. Journal of Medicinal Chemistry, 2017, 60, 7483-7501.	2.9	25
18	The impact of the halogen bonding on D 2 and 5-HT 1A /5-HT 7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. Bioorganic and Medicinal Chemistry, 2017, 25, 3638-3648.	1.4	24

#	Article	IF	Citations
19	Synthesis and SAR-study for novel arylpiperazine derivatives of 5-arylidenehydantoin with Î±1-adrenoceptor antagonistic properties. Bioorganic and Medicinal Chemistry, 2012, 20, 4245-4257.	1.4	23
20	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT_{1A} Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019, 62, 2750-2771.	2.9	21
21	Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	2.6	19
22	Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Neuropharmacology, 2014, 85, 253-262.	2.0	18
23	Novel 5-HT 7 R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile. Bioorganic and Medicinal Chemistry, 2017, 25, 2789-2799.	1.4	18
24	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	1.7	18
25	Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6. European Journal of Medicinal Chemistry, 2019, 178, 740-751.	2.6	18
26	Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro. Molecules, 2019, 24, 4472.	1.7	18
27	Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacological Reports, 2013, 65, 998-1005.	1.5	17
28	Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: Design, synthesis, and antidepressant properties. Part II. European Journal of Medicinal Chemistry, 2015, 92, 202-211.	2.6	16
29	Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1079-1088.	1.4	16
30	Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 839-849.	1.4	16
31	N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT7 receptor selectivity versus multireceptor profile. Bioorganic and Medicinal Chemistry, 2016, 24, 130-139.	1.4	16
32	Metabolic and Cardiovascular Benefits and Risks of EMD386088â€"A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor. Frontiers in Neuroscience, 2017, 11, 50.	1.4	16
33	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT 7 receptor agents with antidepressant activity. European Journal of Medicinal Chemistry, 2018, 147, 102-114.	2.6	16
34	New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation. Pharmacological Reports, 2013, 65, 15-29.	1.5	15
35	Discovery of Novel pERK1/2- or Î²-Arrestin-Preferring 5-HT_{1A} Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. Journal of Medicinal Chemistry, 2020, 63, 10946-10971.	2.9	15
36	Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties inÂvivo. European Journal of Medicinal Chemistry, 2020, 203, 112529.	2.6	14

#	Article	IF	Citations
37	Arylsulfonamide derivatives of (aryloxy)ethylpiperidines as selective 5-HT₇ receptor antagonists and their psychotropic properties. MedChemComm, 2015, 6, 1272-1277.	3.5	13
38	The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opinion on Drug Discovery, 2018, 13, 779-790.	2.5	13
39	Behavioral Pharmacology: Potential Antidepressant and Anxiolytic Properties. International Review of Neurobiology, 2011, 96, 49-71.	0.9	12
40	The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Expert Opinion on Drug Discovery, 2020, 15, 279-292.	2.5	12
41	ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 593-602.	1.4	11
42	The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases. International Journal of Molecular Sciences, 2021, 22, 10773.	1.8	11
43	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1048-1062.	2.5	10
44	Tail suspension test does not detect antidepressant-like properties of atypical antipsychotics. Behavioural Pharmacology, 2011, 22, 7-13.	0.8	8
45	Synthesis and biological investigation of new equatorial (Î²) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile. Bioorganic and Medicinal Chemistry, 2016, 24, 3994-4007.	1.4	8
46	Characteristics of metabolic stability and the cell permeability of 2â€pyrimidinylâ€piperazinylâ€alkyl derivatives of 1Hâ€imidazo[2,1 â€f]purineâ€2,4(3 H ,8 H)â€dione with antidepressantâ€•and anxiolyticâ€like activities. Chemical Biology and Drug Design, 2019, 93, 511-521.	1.5	8
47	An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential. Bioorganic Chemistry, 2022, 121, 105695.	2.0	8
48	Synthesis and Pharmacological Evaluation of Novel Tricyclic[2,1â€f]theophylline Derivatives. Archiv Der Pharmazie, 2013, 346, 832-839.	2.1	7
49	Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. Journal of Pharmacy and Pharmacology, 2014, 66, 1755-1762.	1.2	7
50	Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 37-49.	1.4	7
51	Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. PLoS ONE, 2020, 15, e0237196.	1.1	7
52	Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats. Behavioural Brain Research, 2019, 359, 9-16.	1.2	6
53	Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2105-2127.	1.0	6
54	Chronic antidepressant-like effect of EMD386088, a partial 5-HT6 receptor agonist, in olfactory bulbectomy model may be connected with BDNF and/or CREB signalling pathway. Pharmacological Reports, 2018, 70, 1047-1056.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. Journal of Medicinal Chemistry, 2021, 64, 12603-12629.	2.9	5
56	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). European Journal of Medicinal Chemistry, 2020, 191, 112149.	2.6	4
57	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. European Journal of Medicinal Chemistry, 2022, 233, 114218.	2.6	4
58	Synthesis and biological investigations of 3Î²-aminotropane arylamide derivatives with atypical antipsychotic profile. Medicinal Chemistry Research, 2018, 27, 1906-1928.	1.1	2
59	The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and Î²-arrestin signalling. Journal of Psychopharmacology, 2020, 34, 1431-1442.	2.0	2
60	A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	1.1	2
61	The selective 5-HT1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. Behavioural Pharmacology, 0, Publish Ahead of Print, .	0.8	0